Bortezomib-based antibody depletion for refractory autoimmune hematological diseases by Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S. Kaplan, James D. McFadyen, Huyen Tran, Tse-Chieh Teh, Shaun Fleming, John V. Catalano, Sanjeev D. Chunilal, Anna Johnston, Stephen S. Opat, and Jake Shortt BloodAdv Volume 1(1):31-35 November 29, 2016 © 2016 by The American Society of Hematology

Sumita Ratnasingam et al. Blood Adv 2016;1:31-35 © 2016 by The American Society of Hematology

Representative clinical responses to bortezomib. Representative clinical responses to bortezomib. (A) Time course for laboratory indices in a TTP patient (case #8) with drug treatments administered as indicated. Concurrent frequency of PEX and ADAMTS13 inhibitory activity (in Bethesda units) is annotated beneath. (B) Time course for laboratory indices in a patient with cold AIHA (case #1). Bortezomib was initiated twice weekly (dark shading) and then transitioned to weekly maintenance therapy (gray shading). B, bortezomib; BU, Bethesda unit; LDH, lactate dehydrogenase; ND, not done; R, rituximab; RBC, red blood cell. Sumita Ratnasingam et al. Blood Adv 2016;1:31-35 © 2016 by The American Society of Hematology